Jon Moore

Jon joined Advent in 2018, and brings over 15 years of experience from some of the leading biotech companies in the UK. He has a track record of success in early-stage drug discovery against first in class targets, the application of gene editing to drug discovery, developing new therapeutic technology platforms and in business development. Jon was most recently CSO of Horizon Discovery where he co-founded Avvinity Therapeutics. Prior to that, he was Head of Biology at Vernalis Research.

Jon is originally a biochemist and cell biologist with a PhD from the University of Newcastle upon Tyne and extensive postdoctoral experience in academia including 4 years with Nobel Laureate, Tim Hunt.

Jon plays a key role in Advent’s diligence into pre-clinical small molecule and novel technology platforms.